Enzyme
AIRNA nets $155M series B to launch clinical test of RNA editing tech
RNA Editing, Airna, AIR-001, RNA
FDA clears Exelixis’ TKI for neuroendocrine tumours
CABOMETYX, cabozantinib, neuroendocrine tumors, FDA approval, Exelixis, tyrosine kinase inhibitor
J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca’s Tagrisso
Continuance of life, Combined, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Overall Survival, Tagrisso
Avidity’s Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment
Del-zota, Duchenne muscular dystrophy (DMD), RNA therapeutics, exon 44 skipping, dystrophin production, creatine kinase reduction, safety profile
Incyte’s oral HS drug hits study goals, but fails to excite investors
povorcitinib, JAK1 inhibitor, hidradenitis suppurativa, Phase 3 trials, efficacy, investor reaction, regulatory submission
AstraZeneca Inks $1.35B Deal with Alteogen for Subcutaneous Cancer Drugs Amid Industry Patent Disputes
AstraZeneca, Alteogen, subcutaneous cancer drugs, licensing agreement, patent dispute, Merck, Halozyme, hyaluronidase enzyme
AI-Driven Enzyme Engineering: Baker Lab’s Latest Breakthrough in Computational Protein Design
AI-generated enzymes, computational protein design, artificial luciferases, de novo enzyme engineering, machine learning in biochemistry, Baker Lab, University of Washington
Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects
SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay
Boehringer Ingelheim’s Nerandomilast Succeeds in Second Phase III Lung Fibrosis Trial, Paving Way for FDA Approval
Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive fibrosing interstitial lung diseases (PF-ILDs), lung function improvement, FDA approval, phosphodiesterase 4B (PDE4B) inhibitor
J&J’s Subcutaneous Rybrevant Receives CHMP Backing for Lung Cancer Treatment Despite Recent FDA Rejection
Rybrevant, amivantamab, Johnson & Johnson, CHMP, FDA, subcutaneous formulation, non-small cell lung cancer, EGFR mutations